Degradation of a fluoropyridinyl drug in capsule formulation: degradant identification, proposed degradation mechanism, and formulation optimization.
The purpose of this paper was to investigate the degradation chemistry of a fluoropyridinyl drug candidate in capsule formulation and to optimize the formulation based on a proposed degradation mechanism. Small developmental batches of capsules were made by tituration of drug substance and excipients using a mortar and pestle, followed by manual encapsulation. Degradants were identified by LC-MS/MS and LC-photodiode array detector (PDA) and were monitored by LC-ultraviolet detector (UVD) during stability studies. It was found that the drug could undergo a nucleophilic substitution reaction in which hydroxyl groups replace the fluorine substituents on the pyridine rings. The initial degradation rate is independent of the drug concentration but dependent on the temperature, the pH of the microenvironment, and the excipient type. On the basis of these experimental results, a nucleophilic substitution reaction mechanism for the degradation was proposed and a successful capsule formulation was developed.
Chen
J G
JG
DuPont Pharmaceuticals Company, Wilmington, Delaware 19880, USA. jian-ge.chen@spcorp.com
Markovitz
D A
DA
Yang
A Y
AY
Rabel
S R
SR
Pang
J
J
Dolinsky
O
O
Wu
L S
LS
Alasandro
M
M
D000873:Anthracenes / Q000008:administration & dosage / Q000737:chemistry*; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D002853:Chromatography, Liquid; D004355:Drug Stability; D005079:Excipients; D006863:Hydrogen-Ion Concentration; D013058:Mass Spectrometry; D018697:Nootropic Agents / Q000737:chemistry*; D013696:Temperature
D000873:Anthracenes; D002214:Capsules; D005079:Excipients; D018697:Nootropic Agents; C112296:DMP 543